See highlights from GHTC's 2022 Innovating for Impact Awards

Search the GHTC website

Florida

Florida

Global health R&D delivers for Florida

US government investment in global health R&D has delivered

Amount
$94.1 million
to Florida research institutions
Jobs
1,500+ new jobs
for Florida
Florida

Neglected diseases in Florida

Chikungunya cases
Chikungunya cases
572
Dengue cases
Dengue cases
779
HIV diagnoses
HIV diagnoses
43431
Malaria cases
Malaria cases
604
Tuberculosis cases
Tuberculosis cases
6531
West Nile cases
West Nile cases
160
Zika cases
Zika cases
1216
Florida's top USG-funded global health R&D institutions

Florida's top USG-funded global health R&D institutions

University of Miami (including the Miller School of Medicine)
$22.5 million
University of South Florida
$15.6 million
University of Central Florida
$15.4 million
University of Florida
$12.4 million
Florida State University
$9.7 million
Vaccine and Gene Therapy Institute of Florida
$5.2 million
Florida International University
$4 million
Sanford-Burnham Medical Research Institute
$2.7 million
Florida Atlantic University
$1.1 million
Foundation for Applied Molecular Evolution
$1.1 million
Moffitt Cancer Center
$469 thousand
Florida industry in global health R&D

Florida industry in global health R&D

Alere
Location(s): Orlando
Amgen
Location(s): Tampa
Beckman Coulter
Location(s): Miami
Bristol-Myers Squibb
Location(s): Tampa
Celgene
Location(s): Destin
Cipla
Location(s): Sunrise
Gilead
Location(s): Miami
Novartis
Location(s): Miami, Plantation
Opko
Location(s): Miami
Sanofi
Location(s): Orlando
Vax Design
Location(s): Orlando

Florida's top areas of global health R&D by USG funding

34.5%
HIV/AIDS
19.9%
Malaria
16.9%
Tuberculosis
8.3%
Diarrheal diseases
11.5%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
8.9%
Other
Bacterial pneumonia & meningitis
Salmonella infections
Global health R&D at work in Florida

University of Florida scientists are studying how Florida mosquito species spread chikungunya virus. The virus, which occurs mostly in Africa, Asia, and India, arrived in the Caribbean several years ago; since then, more than 3,800 cases have been diagnosed in Florida. The virus causes fever, headaches, muscle and joint pain, and, in some cases, chronic rheumatoid arthritis. The study will help scientists model chikungunya transmission to better control outbreaks.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: CDC/James Gathany